Log In
Print
BCIQ
Print
Print this Print this
 

Prometheus Anser IFX

  Manage Alerts
Collapse Summary General Information
Company Nestle S.A.
DescriptionQuantitative monitoring assay that uses Prometheus' homogenous mobility shift assay (HMSA) technology to detect and measure serum infliximab and infliximab antibodies
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationGastrointestinal, Diagnostic
Indication DetailsIdentify causes of loss of infliximab treatment response in patients with Crohn's disease (CD); Identify causes of loss of infliximab treatment response in patients with inflammatory bowel disease (IBD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today